Centocor Warns Doctors About Heightened Lymphoma Risk With Patients Who Take Remicade The Associated Press WASHINGTON Oct. 7, 2004 — Patients taking Remicade for rheumatoid arthritis suffered a type of cancer, lymphoma, at three times the rate of the general public, manufacturer Centocor warned doctors on Thursday. Centocor, a subsidiary of Johnson & Johnson, said the lymphoma incidence rate was six times higher among all patients who took the monoclonal antibody in completed clinical trials. Experts said such toxic outcomes, however, are still rare, and that the new drugs, on balance, work markedly better than older medications, without such side...